One-Month DAPT in CABG Patients (ODIN)
Chronic Coronary Disease
About this trial
This is an interventional prevention trial for Chronic Coronary Disease
Eligibility Criteria
Inclusion Criteria: Age ≥18 years Elective first-time CABG with use of ≥1 saphenous vein graft; Ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years. Exclusion Criteria: Any indication for dual antiplatelet therapy, including Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI) Recent PCI requiring continuation of dual antiplatelet therapy after CABG Current or anticipated use of oral anticoagulation; Paroxysmal, persistent or permanent atrial fibrillation; Any concomitant cardiac or non-cardiac procedure; Planned cardiac or non-cardiac surgery within one year; Preoperative end-organ dysfunction (dialysis, moderate to severe liver failure, respiratory failure), cancer or other non-cardiac comorbidity with a life expectancy <5 years; Inability to use the saphenous vein; Contraindications to the use of aspirin; Contraindications to the use of ticagrelor, including Known hypersensitivity to ticagrelor Active pathological bleeding (including, but not limited to gastrointestinal or intracranial bleeding) History of intracranial hemorrhage Concomitant therapy with strong CYP3A4 inhibitors (eg ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir) Inability to undergo coronary computed tomographic angiography (CCTA); Participating in another investigational device or drug study; Women of childbearing potential Any major perioperative complication including, but not limited to, stroke, TIA, MI, CABG-related bleeding (BARC type 4), sepsis.
Sites / Locations
- Weill Cornell Medicine
- Medical University Graz
- Medical University Innsbruck
- Johannes Kepler University Linz
- Medical University of Vienna
- University of Ottawa Heart Institute
- Westdeutsches Herz- und Gefäßzentrum Essen, Universität Duisburg-Essen
- Klinik für Herz- und Gefäßchirurgie - Universitäts-Herzzentrum Freiburg - Bad Krozingen
- Universitätsklinikum Giessen
- LMU Klinikum Campus Großhadern
- Robert-Bosch-Krankenhaus Stuttgart
- Sahlgrenska University Hospital Sweden
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Ticagrelor 90 mg
Ticagrelor placebo